5 results match your criteria: "Department of Gastroenterology and Hepatology Gunma University Graduate School of Medicine Maebashi Japan.[Affiliation]"
Article Synopsis
- An 81-year-old man had surgery to remove part of his liver due to cancer and was diagnosed with combined hepatocellular and cholangiocarcinoma (CHC).
- Thirteen months later, he developed multiple lymph node metastases, indicating the cancer had spread.
- He was treated with a combination of atezolizumab and bevacizumab (Atez/Bev), resulting in a 7.5-month period without disease progression, suggesting this treatment may work well for CHC patients.
Background And Aim: This retrospective study investigated the effect of 48-week pemafibrate therapy in non-alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase (FAST) score.
Methods: A total of 31 NAFLD patients who were treated with pemafibrate in Gunma Saiseikai Maebashi Hospital and Kusunoki Hospital from September 2018 to April 2020 were included in the current study. We used the FAST score, which is a novel index of steatohepatitis that can be calculated based on the AST value, controlled attenuation parameter (CAP), and liver stiffness measurement (LSM), to evaluate the effect of pemafibrate treatment.
We herein report a case of Guillain-Barré syndrome (GBS) after SARS-CoV-2 infection. The patient was a close contact with a SARS-CoV-2 patient. Initially, she did not have any symptoms and quarantined at a hotel.
View Article and Find Full Text PDFNoonan syndrome is a genetic multisystem disorder and is associated with mutation of genes encoding the proteins in the RAS-MAPK pathway. We reported the first case of Noonan syndrome complicated with hepatocellular carcinoma.
View Article and Find Full Text PDFBackground And Aim: We investigated the prognosis of late elderly patients (≥75 years old) after the achievement of a sustained viral response (SVR) by direct-acting antivirals (DAAs).
Methods: One hundred and four late elderly patients and 251 young patients (≤74 years old) who had achieved an SVR were included. We compared the cumulative hepatocellular carcinoma (HCC) incidence rates and survival rates after DAA administration.